RE:RE:RE:EU approves first I/O combinationSo, we have some history with both Pfizer and Roche. Are these drugs a threat to the success of Pela or do they help to verify the science behind Pela. My question really is the following, is Oncy competing to get to market with other therapies or does their targeted approach put Pela on a track that is not pursued by other biotechs, as far as we know?
Another question I have.... because Pela is not a stand alone treatment does it negatively affect it's attractiveness to big Pharma, thereby possibly prevent them from putting up big bucks?
Just thinking out loud and wondering if I make sense.